Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types
MWN-AI** Summary
Biodesix, in collaboration with Bio-Rad Laboratories, has contributed to significant new findings published in *Clinical Cancer Research* as part of the Friends of Cancer Research's ctMoniTR Project. This research highlights a strong correlation between changes in circulating tumor DNA (ctDNA) levels and treatment outcomes in patients with various solid tumors, suggesting potential clinical applications for ctDNA analysis in therapeutic development and patient care.
Initially focused on advanced non-small cell lung cancer (aNSCLC) and immune checkpoint inhibitors, the ctMoniTR Project expanded to investigate additional solid tumor types and treatment modalities, including tyrosine kinase inhibitors. Biodesix played a critical role by providing data collected through Bio-Rad's Droplet Digital PCR (ddPCR) technology, which enables sensitive ctDNA detection from patient samples. This project's findings could pave the way for innovative approaches in monitoring treatment responses and enhancing overall patient survival.
Gary Pestano, PhD, Chief Development Officer at Biodesix, emphasized the project’s alignment with the company’s mission to advance therapeutic development and improve clinical decision-making. Similarly, Bio-Rad's Vice President of Product Management, Steve Kulisch, highlighted the importance of this research in establishing novel methods for molecular residual disease monitoring in oncology.
Beyond this initiative, Biodesix continues to explore ctDNA testing and its integration with proteomics as a means to detect molecular residual disease (MRD). The organization plans to share new advancements in this area at the upcoming American Association for Cancer Research Annual Meeting, scheduled for April 28, 2025. Through partnerships and technological innovations, both Biodesix and Bio-Rad are committed to improving cancer care and developing effective diagnostic solutions.
MWN-AI** Analysis
Biodesix, Inc. (Nasdaq: BDSX) is positioned at an interesting intersection of oncology diagnostics and therapeutic development, especially following the recent publication of findings from the ctMoniTR Project by its partner, Friends of Cancer Research. The project demonstrated a robust correlation between circulating tumor DNA (ctDNA) levels and treatment outcomes across multiple solid tumor types. This presents a crucial opportunity for Biodesix to enhance its diagnostic offerings, which already include ctDNA testing powered by Bio-Rad’s Droplet Digital PCR technology.
Given the promising results of ctMoniTR, investors should consider the implications of incorporating ctDNA analysis into broader clinical decision-making frameworks. The ability to predict treatment outcomes could significantly streamline patient management and lead to more personalized approaches in oncology treatment. This transformative potential aligns with Biodesix’s strategic goal to innovate within clinical cancer care.
From a financial perspective, Biodesix holds potential for growth. The increasing emphasis on precision medicine makes its offerings, particularly in ctDNA testing, more relevant than ever. The company's partnership with established entities like Bio-Rad adds credibility and expands its R&D capabilities. As more oncology practices integrate ctDNA testing into their protocols, Biodesix may see increased demand for its diagnostic services, potentially driving revenue growth.
Additionally, upcoming presentations, such as at the American Association for Cancer Research (AACR) Annual Meeting, could catalyze interest in Biodesix’s innovations, further reinforcing its market position. However, investors should remain aware of the competitive landscape and regulatory hurdles in the diagnostics sector. Therefore, while Biodesix shows significant upside potential, a cautious approach considering both market dynamics and the company’s performance metrics is prudent before making investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
LOUISVILLE, Colo. and HERCULES, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc (Nasdaq: BDSX), a leading diagnostics solutions company, and Bio-Rad Laboratories (NYSE: BIO), a global leader in life science research and diagnostics products, contributed to new research findings from Friends of Cancer Research’s (Friends’ ) ctMoniTR Project , recently published in Clinical Cancer Research (CCR). The findings demonstrate a strong association between changes in levels of circulating tumor DNA (ctDNA) and treatment outcomes, offering the potential for integration of ctDNA analysis in therapeutic development programs, and clinical cancer care.
The ctMoniTR Project (ctDNA to Monitor Treatment Response) was designed to determine whether changes in levels of ctDNA predict treatment outcomes for patients. Results from the first phase of the project demonstrated a strong link between changes in ctDNA and overall survival in patients with aNSCLC treated with immune checkpoint inhibitors (published in the Journal of Clinical Oncology). The new data, from the second phase of ctMoniTR, expands the analysis to additional solid tumor types and treatment categories, including patients treated with tyrosine kinase inhibitors.
Led by Friends, collaborators included Biodesix alongside organizations from industry, government, academia, and advocacy groups. Biodesix contributed data generated using Bio-Rad Droplet Digital™ PCR (ddPCR™) * technology to detect ctDNA from patient samples.
“Biodesix is proud to be a partner on this important project, which has the potential to support a transformation of therapeutic development and clinical cancer care,” said Gary Pestano, PhD, Chief Development Officer at Biodesix. “The ctMoniTR Project is aligned with the mission and vision of Biodesix Development Services, as we strive to challenge the science and solutions of today, in order to evolve and adapt clinical decision-making to improve patient care and outcomes.”
“We are very pleased that Droplet Digital™ PCR (ddPCR™) was selected for use within this study,” said Steve Kulisch, Vice President Product Management, Digital Biology Group, Bio-Rad Laboratories. “These collaborations and research programs are vital as we work towards establishing novel methods for molecular residual disease monitoring in oncology, supporting the advancement of scientific research and ultimately healthcare.”
Beyond this specific research project, Biodesix offers ctDNA testing, using ddPCR technology, as part of its Development Services portfolio and is also exploring ctDNA in combination with proteomics to detect molecular residual disease (MRD). The latest advancements in this application will be presented at the American Association for Cancer Research (AACR) Annual Meeting, April 28 th , 2025.
*Droplet Digital and ddPCR are trademarks of Bio-Rad Laboratories, Inc.
Media Contacts:
Biodesix, Inc.
Natalie St. Denis, Director Corporate Communications
+1 720-925-9285
Natalie.stdenis@biodesix.com
Bio-Rad Laboratories, Inc.
Katrina Academia, Inbound Marketing Manager
+1 510-356-7909
Katrina_academia@bio-rad.com
Zyme Communications (Bio-Rad PR firm)
Dr. Maria Spyrou
+44 (0) 7707 049 640
maria.spyrou@zymecommunications.com
To opt out from receiving press releases from Zyme Communications, please e-mail info@zymecommunications.com . To view our privacy policy, click here .
About Biodesix
Biodesix, Inc. (Nasdaq: BDSX) is a leading diagnostic solutions company, driven to improve clinical care and outcomes for patients. Biodesix Diagnostic Tests, including Nodify Lung® Nodule Risk Assessment and IQLung™ Cancer Treatment Guidance, support clinical decisions to expedite personalized care and improve outcomes for patients with lung disease. Biodesix Development Services enable the world’s leading biopharmaceutical, life sciences, and research institutions with scientific, technological, and operational capabilities that fuel the development of diagnostic tests, tools, and therapeutics across disease states. For more information, visit biodesix.com.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,700 employees and $2.7 billion in revenues in 2023. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com .
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our products and our expectations about our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include global economic and geopolitical conditions, our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, supply chain risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in both Biodesix and Bio-Rad's public reports filed with the Securities and Exchange Commission, including our most recent Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q. Biodesix and Bio-Rad caution you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.
FAQ**
How do the findings from the ctMoniTR Project, involving Bio-Rad Laboratories Inc. Class A BIO, impact the future development of cancer diagnostics and treatment response monitoring?
What specific advancements in ctDNA analysis are expected from Biodesix and Bio-Rad Laboratories Inc. Class A BIO's collaboration, especially in the context of solid tumor types and new treatment categories?
In what ways could the integration of ctDNA analysis influence clinical decision-making for oncology, as highlighted by Biodesix's role alongside Bio-Rad Laboratories Inc. Class A BIO?
What challenges do Biodesix and Bio-Rad Laboratories Inc. Class A BIO anticipate in translating the research outcomes from the ctMoniTR Project into practical clinical applications for cancer care?
**MWN-AI FAQ is based on asking OpenAI questions about Biodesix Inc. (NASDAQ: BDSX).
NASDAQ: BDSX
BDSX Trading
0.82% G/L:
$15.38 Last:
7,050 Volume:
$14.85 Open:
